Despite the ongoing turmoil over tariffs, medicine costs, and FDA policy, US wholesalers are performing well.

Pharma Wholesalers: Looking for Growth

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can safeguard profitability in a volatile market.

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.

340B Litigation and the Path Toward Transparent Drug Discount Programs

Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - August 2025

. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

Beginning Oct. 1, the US will impose a 100% tariff on branded and patented pharmaceutical imports unless manufacturers are actively building domestic production facilities, a move aimed at reshoring drug manufacturing.

Trump Announces 100% Tariff on Branded Drugs Unless Pharma Builds US Plants

Capturing insights from executives and industry experts on the biggest challenges shaping pharma today, from drug pricing pressures and access barriers to supply chain shifts, digital adoption, and evolving patient-centered care strategies.

Pharma Commerce's 2025 State of the Industry Survey

Podcasts

This episode of Pharma Pulse covers new research showing Medicaid cuts could widen pediatric coverage gaps, clinical trial data on a fixed-dose combination therapy lowering heart failure risk in type 2 diabetes, and Bristol Myers Squibb’s launch of a direct-to-patient program for Sotyktu to improve psoriasis treatment access.

Pharma Pulse: Medicaid Cuts Threaten Childhood Coverage, Fixed-Dose Combo Reduces Heart Failure in Diabetes, and BMS Expands Sotyktu Access

Through its “BMS Patient Connect” platform, the company is lowering out-of-pocket costs and providing nationwide shipping, making the treatment for affordable and accessible for US patients.

Bristol Myers Squibb Expands Direct-to-Patient Access With New Sotyktu Program

Videos

Ullrich Mayeski, community engagement director of health with GS1 US, emphasizes the critical need to address interoperability challenges at the dispenser level, ranging from small independent pharmacies to large hospital systems. 

HDA 2025 Traceability Seminar: Closing Gaps in Pharma’s Supply Chain

This episode of Pharma Pulse covers the CDC’s unanimous vote to broaden COVID-19 vaccine recommendations for all adults, new data showing the Medicare Part D Senior Savings Model lowers insulin costs and improves care, and Eli Lilly’s investment in a new Houston manufacturing facility to support its fast-growing pipeline.

Pharma Pulse: CDC Expands COVID-19 Vaccine Guidance, Medicare Model Cuts Insulin Costs, and Lilly Invests in Houston Facility

Ullrich Mayeski, community engagement director of health with GS1 US, outlines how manufacturers, distributors, and dispensers can strengthen end-to-end traceability. 

HDA 2025 Traceability Seminar: Building a Secure and Interoperable Supply Chain

The Generation Park site will create over 600 permanent jobs, support advanced small molecule production, and play a role in scaling orforglipron, Lilly’s first oral GLP-1 receptor agonist for obesity.

Eli Lilly to Invest $6.5 Billion in New Houston Manufacturing Facility

This episode of Pharma Pulse covers the FDA’s review of a possible link between prenatal acetaminophen use and autism, GSK’s supplemental new drug application to update leucovorin labeling, and Celltrion’s acquisition of an Eli Lilly production facility to expand biologics manufacturing capacity.

Pharma Pulse: FDA Examines Prenatal Acetaminophen Risks, GSK Files sNDA for Leucovorin, and Celltrion Buys Lilly Plant

Ullrich Mayeski, community engagement director of health with GS1 US, explains how with over a decade of collaboration, manufacturers and distributors are largely prepared for DSCSA compliance. The remaining challenge lies in ensuring consistent readiness across dispensers, while maintaining open communication throughout the supply chain.

Featured Content

Pharma Wholesalers: Looking for Growth

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

340B Litigation and the Path Toward Transparent Drug Discount Programs

Pharmaceutical Commerce - August 2025